Habibollah Dadgar, Nasim Norouzbeigi, Majid Assadi, Batool Al-Balooshi, Akram Al-Ibraheem, Abdulredha A Esmail, Fahad Marafi, Mohamad Haidar, Haider Muhsin Al-Alawi, Yehia Omar, Sharjeel Usmani, Andrea Cimini, Hossein Arabi, Habib Zaidi
{"title":"使用 68Ga-FAPI-46 PET/CT 检测各种癌症类型的初步临床经验。","authors":"Habibollah Dadgar, Nasim Norouzbeigi, Majid Assadi, Batool Al-Balooshi, Akram Al-Ibraheem, Abdulredha A Esmail, Fahad Marafi, Mohamad Haidar, Haider Muhsin Al-Alawi, Yehia Omar, Sharjeel Usmani, Andrea Cimini, Hossein Arabi, Habib Zaidi","doi":"10.1967/s002449912723","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Numerous studies have shown that gallium-68-labeled fibroblast activation protein inhibitor (<sup>68</sup>Ga-FAPI) positron emission tomography/computed tomography (PET/CT) scans would yield high intra-tumoral tracer uptake and low uptake in normal tissues as background, thus allowing for excellent visualization of lesions in the cancer microenvironment. This study set out to compare the suitability of novel <sup>68</sup>Ga-FAPI-46 PET versus routine fluorine-18-fluorodeoxyglucose (<sup>18</sup>F-FDG) PET and other few cases of <sup>68</sup>Ga-DOTATATE/<sup>68</sup>Ga-Pentixafor PET/CT for the assessment of different types of cancer.</p><p><strong>Subjects and methods: </strong>A retrospective analysis of 11 patients (6 males, 5 females; average age: 53 years, range: 10-58 years) with histopathologically confirmed, well-differentiated adenocarcinoma, medullar thyroid cancer (MTC), papillary thyroid carcinoma (PTC), cervical, gastric, glioblastoma multiform (GBM), colon, Ewing's sarcoma, and breast cancer was performed. These patients underwent PET/CT scans using four different radiotracers (9 <sup>18</sup>F-FDG, 11 <sup>68</sup>Ga- FAPI, 3 <sup>68</sup>Ga-DOTATATE, and 1 <sup>68</sup>Ga-Pentixafor). The patients' PET/CT images were visually evaluated for cancer detection, and analyzed semi-quantitatively through image- derived metrics, such as target-to-background ratio (TBR) and maximum standardized uptake value (SUVmax), for recurrence and metastasis.</p><p><strong>Results: </strong>The study of 11 patients revealed that <sup>68</sup>Ga-FAPI-46 was more effective than other tracers for detecting metastases, with 55 vs. 49 metastases in the lymph nodes, 4 vs. 3 in the liver, and 4 vs. 3 in the bones detected in comparison to <sup>18</sup>F-FDG. No significant differences were observed in <sup>68</sup>Ga-DOTATATE and <sup>68</sup>Ga-Pentixafor PET images. In addition, in five patients, the SUVmax and TBR values in <sup>68</sup>Ga-FAPI-46 PET images were significantly higher than those in <sup>18</sup>F-FDG PET images for lymph nodes and bone metastases. Although the SUVmax in <sup>68</sup>Ga-FAPI-46 and <sup>18</sup>F-FDG PET images for liver metastases was comparable, <sup>68</sup>Ga-FAPI- 46 had a significantly higher TBR than <sup>18</sup>F-FDG.</p><p><strong>Conclusion: </strong>Our findings suggest that FAPI PET/CT is not suitable for evaluating GBM and Ewing sarcoma but generally outperforms <sup>18</sup>F-FDG PET/CT in various types of breast cancer, gastrointestinal, gynecological, PTC and MTC. However, larger trials are needed to validate these preliminary findings.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Initial clinical experience using <sup>68</sup>Ga-FAPI-46 PET/CT for detecting various cancer types.\",\"authors\":\"Habibollah Dadgar, Nasim Norouzbeigi, Majid Assadi, Batool Al-Balooshi, Akram Al-Ibraheem, Abdulredha A Esmail, Fahad Marafi, Mohamad Haidar, Haider Muhsin Al-Alawi, Yehia Omar, Sharjeel Usmani, Andrea Cimini, Hossein Arabi, Habib Zaidi\",\"doi\":\"10.1967/s002449912723\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Numerous studies have shown that gallium-68-labeled fibroblast activation protein inhibitor (<sup>68</sup>Ga-FAPI) positron emission tomography/computed tomography (PET/CT) scans would yield high intra-tumoral tracer uptake and low uptake in normal tissues as background, thus allowing for excellent visualization of lesions in the cancer microenvironment. This study set out to compare the suitability of novel <sup>68</sup>Ga-FAPI-46 PET versus routine fluorine-18-fluorodeoxyglucose (<sup>18</sup>F-FDG) PET and other few cases of <sup>68</sup>Ga-DOTATATE/<sup>68</sup>Ga-Pentixafor PET/CT for the assessment of different types of cancer.</p><p><strong>Subjects and methods: </strong>A retrospective analysis of 11 patients (6 males, 5 females; average age: 53 years, range: 10-58 years) with histopathologically confirmed, well-differentiated adenocarcinoma, medullar thyroid cancer (MTC), papillary thyroid carcinoma (PTC), cervical, gastric, glioblastoma multiform (GBM), colon, Ewing's sarcoma, and breast cancer was performed. These patients underwent PET/CT scans using four different radiotracers (9 <sup>18</sup>F-FDG, 11 <sup>68</sup>Ga- FAPI, 3 <sup>68</sup>Ga-DOTATATE, and 1 <sup>68</sup>Ga-Pentixafor). The patients' PET/CT images were visually evaluated for cancer detection, and analyzed semi-quantitatively through image- derived metrics, such as target-to-background ratio (TBR) and maximum standardized uptake value (SUVmax), for recurrence and metastasis.</p><p><strong>Results: </strong>The study of 11 patients revealed that <sup>68</sup>Ga-FAPI-46 was more effective than other tracers for detecting metastases, with 55 vs. 49 metastases in the lymph nodes, 4 vs. 3 in the liver, and 4 vs. 3 in the bones detected in comparison to <sup>18</sup>F-FDG. No significant differences were observed in <sup>68</sup>Ga-DOTATATE and <sup>68</sup>Ga-Pentixafor PET images. In addition, in five patients, the SUVmax and TBR values in <sup>68</sup>Ga-FAPI-46 PET images were significantly higher than those in <sup>18</sup>F-FDG PET images for lymph nodes and bone metastases. Although the SUVmax in <sup>68</sup>Ga-FAPI-46 and <sup>18</sup>F-FDG PET images for liver metastases was comparable, <sup>68</sup>Ga-FAPI- 46 had a significantly higher TBR than <sup>18</sup>F-FDG.</p><p><strong>Conclusion: </strong>Our findings suggest that FAPI PET/CT is not suitable for evaluating GBM and Ewing sarcoma but generally outperforms <sup>18</sup>F-FDG PET/CT in various types of breast cancer, gastrointestinal, gynecological, PTC and MTC. However, larger trials are needed to validate these preliminary findings.</p>\",\"PeriodicalId\":12871,\"journal\":{\"name\":\"Hellenic journal of nuclear medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hellenic journal of nuclear medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1967/s002449912723\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hellenic journal of nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1967/s002449912723","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/6 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Initial clinical experience using 68Ga-FAPI-46 PET/CT for detecting various cancer types.
Objective: Numerous studies have shown that gallium-68-labeled fibroblast activation protein inhibitor (68Ga-FAPI) positron emission tomography/computed tomography (PET/CT) scans would yield high intra-tumoral tracer uptake and low uptake in normal tissues as background, thus allowing for excellent visualization of lesions in the cancer microenvironment. This study set out to compare the suitability of novel 68Ga-FAPI-46 PET versus routine fluorine-18-fluorodeoxyglucose (18F-FDG) PET and other few cases of 68Ga-DOTATATE/68Ga-Pentixafor PET/CT for the assessment of different types of cancer.
Subjects and methods: A retrospective analysis of 11 patients (6 males, 5 females; average age: 53 years, range: 10-58 years) with histopathologically confirmed, well-differentiated adenocarcinoma, medullar thyroid cancer (MTC), papillary thyroid carcinoma (PTC), cervical, gastric, glioblastoma multiform (GBM), colon, Ewing's sarcoma, and breast cancer was performed. These patients underwent PET/CT scans using four different radiotracers (9 18F-FDG, 11 68Ga- FAPI, 3 68Ga-DOTATATE, and 1 68Ga-Pentixafor). The patients' PET/CT images were visually evaluated for cancer detection, and analyzed semi-quantitatively through image- derived metrics, such as target-to-background ratio (TBR) and maximum standardized uptake value (SUVmax), for recurrence and metastasis.
Results: The study of 11 patients revealed that 68Ga-FAPI-46 was more effective than other tracers for detecting metastases, with 55 vs. 49 metastases in the lymph nodes, 4 vs. 3 in the liver, and 4 vs. 3 in the bones detected in comparison to 18F-FDG. No significant differences were observed in 68Ga-DOTATATE and 68Ga-Pentixafor PET images. In addition, in five patients, the SUVmax and TBR values in 68Ga-FAPI-46 PET images were significantly higher than those in 18F-FDG PET images for lymph nodes and bone metastases. Although the SUVmax in 68Ga-FAPI-46 and 18F-FDG PET images for liver metastases was comparable, 68Ga-FAPI- 46 had a significantly higher TBR than 18F-FDG.
Conclusion: Our findings suggest that FAPI PET/CT is not suitable for evaluating GBM and Ewing sarcoma but generally outperforms 18F-FDG PET/CT in various types of breast cancer, gastrointestinal, gynecological, PTC and MTC. However, larger trials are needed to validate these preliminary findings.
期刊介绍：
The Hellenic Journal of Nuclear Medicine published by the Hellenic Society of
Nuclear Medicine in Thessaloniki, aims to contribute to research, to education and
cover the scientific and professional interests of physicians, in the field of nuclear
medicine and in medicine in general. The journal may publish papers of nuclear
medicine and also papers that refer to related subjects as dosimetry, computer science,
targeting of gene expression, radioimmunoassay, radiation protection, biology, cell
trafficking, related historical brief reviews and other related subjects. Original papers
are preferred. The journal may after special agreement publish supplements covering
important subjects, dully reviewed and subscripted separately.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
